John Amos, Vivus CEO
July 13, 2022 01:42 PM EDTUpdated 05:55 PM
Pharma

Vivus’ Qsymia beats out weight loss com­peti­tors in pric­ing watch­dog's lat­est cost-ef­fec­tive­ness analy­sis

Paul Schloesser

Associate Editor

Cost-ef­fec­tive­ness watch­dog ICER took a look at sev­er­al dif­fer­ent drugs ap­proved for obe­si­ty and weight loss — and to them, there is a clear win­ner. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times